candesartan + placebo

Phase 3UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Aortic Valve Stenosis

Conditions

Aortic Valve Stenosis

Trial Timeline

May 1, 2009 → Dec 1, 2014

NCT ID

NCT00699452

About candesartan + placebo

candesartan + placebo is a phase 3 stage product being developed by AstraZeneca for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00699452. Target conditions include Aortic Valve Stenosis.

What happened to similar drugs?

6 of 13 similar drugs in Aortic Valve Stenosis were approved

Approved (6) Terminated (4) Active (5)

❌Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3

🔄EdoxabanDaiichi SankyoPhase 3

✅NOAC + DAPTDaiichi SankyoApproved

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

✅SugammadexMerckApproved

✅bisoprolol + placeboMerckApproved

✅atorvastatin (Lipitor)PfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00699452	Phase 3	UNKNOWN	May 1, 2009	Dec 1, 2014	Aortic Valve Stenosis
NCT00319202	Approved	Terminated	Jun 1, 2006	Feb 1, 2012	Glucose Intolerance
NCT00328302	Approved	UNKNOWN	Sep 1, 2000	Apr 1, 2006	Diabetes, Type I
NCT00634712	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634309	Phase 3	Completed	Jun 1, 1999	May 1, 2003	Congestive Heart Failure
NCT00634400	Phase 3	Completed	Mar 1, 1999	May 1, 2003	Congestive Heart Failure

Competing Products

20 competing products in Aortic Valve Stenosis

See all competitors

Product	Company	Stage	Hype Score
Apixaban 5 MG + Apixaban 2.5 MG + Warfarin	Artivion	Phase 3	26
Edoxaban	Daiichi Sankyo	Phase 3	36
NOAC + DAPT	Daiichi Sankyo	Approved	43
Ticagrelor + Placebo	AstraZeneca	Phase 2	35
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Sugammadex	Merck	Approved	43
bisoprolol + placebo	Merck	Approved	35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	42
Pelacarsen (TQJ230) 80mg + Matching placebo	Novartis	Phase 2	42
fluvastatin	Novartis	Phase 2	31
ACZ885 + Placebo	Novartis	Phase 2	27
Evolocumab + Placebo	Amgen	Phase 1	36
atorvastatin (Lipitor)	Pfizer	Approved	35
Apixaban + Standard of care	Pfizer	Phase 3	40
Ataciguat + Placebo	Sanofi	Phase 1	29
Ataciguat (HMR1766)	Sanofi	Phase 2	35
Haemocomplettan® P + Saline solution	CSL	Phase 2	35
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)	Bayer	Phase 3	29
Acetylsalicylic acid + Clopidogrel + Rivaroxaban	Bayer	Phase 3	37
Desflurane	Baxter	Approved	36